Pinnaql Acquires Pharma Resource Group, Cementing Strategy to Build End-to-End Life Sciences Platform

FISHERS, IN & ROYERSFORD, PA – April 30, 2026 – Pinnaql, Inc. today announced its acquisition of Pharma Resource Group, Inc. (PRG), a strategic move that significantly broadens its scientific and manufacturing advisory capabilities. The deal marks the third tuck-in acquisition for the rapidly growing life sciences consulting firm in just ten months, signaling an aggressive, private equity-backed strategy to consolidate a fragmented market and create a comprehensive service platform.

Backed by 3 Boomerang Capital, Pinnaql is methodically assembling a full-spectrum advisory service designed to guide pharmaceutical and biotech companies from the earliest stages of development to full commercial readiness. The addition of PRG, a firm specializing in analytical sciences, formulation, and manufacturing processes, adds a critical layer of scientific expertise to Pinnaql's established strengths.

"The addition of PRG marks another major step in building Pinnaql into the partner life sciences companies can rely on, from development to commercial readiness," said John Duffin, Chief Executive Officer of Pinnaql. "By combining PRG's scientific development and scale-up expertise with our established strengths in validation, engineering, quality systems, and regulatory compliance, we can now support clients throughout their full spectrum of growth."

The Private Equity Playbook in Action

This acquisition is a textbook example of a private equity “buy and build” strategy, orchestrated by 3 Boomerang Capital (3BC), a firm focused on the lower-middle-market healthcare sector. Since closing its flagship $376 million fund in early 2024, 3BC has been actively deploying capital to create scaled platforms in high-growth areas. The development of Pinnaql is a primary exhibit of this strategy.

The journey began in June 2025 when 3BC established LSOMS Holdings and made Pinnaql its foundational acquisition, creating a platform for quality and regulatory consulting. Just two months later, in August 2025, Pinnaql acquired the Validation & Engineering Group, Inc. (VEG), bolstering its capabilities in manufacturing compliance. The PRG acquisition now represents the third and most recent piece of this expanding puzzle, adding deep scientific and formulation know-how.

This series of acquisitions reflects 3BC’s thesis of backing founder-led businesses and providing the resources for rapid growth. The firm's investments in other platforms, such as Analytical Biological Services Inc. and Enjoin, LLC, show a consistent pattern of acquiring a core company and then executing strategic tuck-in acquisitions to expand service lines and market share.

"We are pleased to support Pinnaql's ongoing growth through strategic acquisitions that expand its capabilities and market reach," commented Peter Wen, Principal at 3 Boomerang Capital. "PRG enhances the platform's technical depth and further positions Pinnaql as a differentiated partner to life sciences organizations."

Forging an End-to-End Life Sciences Partner

The strategic fit between Pinnaql and PRG is central to the deal's value proposition. Before the acquisition, Pinnaql was already a respected name in GxP compliance, validation, engineering, and quality systems—services crucial for navigating the complex regulatory landscape of drug and device manufacturing. However, PRG, founded in 2007, brings a different and highly complementary set of skills focused on the earlier stages of product development.

PRG's expertise in analytical sciences, product formulation, and manufacturing scale-up allows the combined entity to engage with clients much earlier in the product lifecycle. This creates a seamless support system that can guide a therapy from laboratory benchtop to full-scale production and regulatory submission. For clients, this integrated approach promises to break down silos, reduce the number of vendors they need to manage, and de-risk the notoriously difficult transition from research to commercial manufacturing.

Duffin highlighted this benefit, stating, "From laboratory innovation to manufacturing readiness, we help organizations reduce execution risk, avoid compliance setbacks, and bring therapies to market with greater speed and confidence."

Tapping into a Fragmented, High-Growth Market

Pinnaql's expansion is occurring within a burgeoning and dynamic market. The global life sciences consulting sector is on a steep growth trajectory, with some projections estimating it will exceed $84 billion by 2034. This growth is fueled by several powerful tailwinds, including increasingly complex global regulatory requirements, the rapid rise of advanced therapies like cell and gene therapy, and the transformative impact of digital technologies such as AI and big data analytics.

Simultaneously, the market remains highly fragmented, populated by numerous small and mid-sized specialized firms. This fragmentation creates a significant opportunity for consolidators like Pinnaql and its backer, 3 Boomerang Capital. By acquiring and integrating these niche players, they can build a platform that offers the scale and breadth of services that large pharmaceutical companies and even well-funded biotech startups increasingly demand.

Private equity firms have taken notice, deploying significant capital to capitalize on the sector's resilience and growth prospects. The “buy and build” model is particularly effective here, as it allows for the rapid assembly of a multi-disciplinary powerhouse capable of competing for larger, more complex contracts.

The New Model for Life Sciences Support

This acquisition also reflects a fundamental shift in the relationship between life sciences companies and their external partners. In the past, companies might hire consultants for discrete, specialized tasks. Today, facing immense pressure to accelerate innovation while controlling costs, they are seeking holistic strategic partners.

Biotech startups, often rich in scientific innovation but lean on internal regulatory and manufacturing infrastructure, rely heavily on external expertise to navigate the path to market. Large pharma, meanwhile, is increasingly outsourcing non-core functions to streamline operations and focus on pipeline execution. In both cases, the demand is for an integrated partner who understands the entire product lifecycle and can provide seamless, end-to-end support.

By combining PRG's scientific acumen with its own regulatory and quality prowess, Pinnaql is positioning itself to be that indispensable partner. The company's mission to deliver expert-driven solutions that accelerate innovation is now backed by a more comprehensive toolkit. This strategic expansion is not just about growing a business; it's about building an integrated engine designed to help clients more efficiently navigate the complex journey of bringing new, life-changing therapies to the patients who need them.